[go: up one dir, main page]

US20090221673A1 - Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat - Google Patents

Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat Download PDF

Info

Publication number
US20090221673A1
US20090221673A1 US12/064,471 US6447106A US2009221673A1 US 20090221673 A1 US20090221673 A1 US 20090221673A1 US 6447106 A US6447106 A US 6447106A US 2009221673 A1 US2009221673 A1 US 2009221673A1
Authority
US
United States
Prior art keywords
hnrnp
agent
cell
expression
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/064,471
Other languages
English (en)
Inventor
William F. C. Rigby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/064,471 priority Critical patent/US20090221673A1/en
Assigned to TRUSTEES OF DARTMOUTH COLLEGE reassignment TRUSTEES OF DARTMOUTH COLLEGE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RIGBY, WILLIAM F.C.
Publication of US20090221673A1 publication Critical patent/US20090221673A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: DARTMOUTH COLLEGE
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: TRUSTEES OF DARTMOUTH COLLEGE
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Definitions

  • CD154 CD40 ligand
  • TNF Tumor Necrosis Factor
  • CD154 blockade retards the development and progression of immune responses in an array of transplantation and autoimmune disease models ranging from Systemic Lupus Erythematosus to Rheumatoid Arthritis to Multiple Sclerosis (Foy, et al. (1996) supra; Grewal & Flavell (1998) supra). Resting T cells express little or no CD154 (Lane, et al. (1992) Eur. J. Immunol. 22:2573-2578; Nusslein, et al. (1996) Eur. J. Immunol. 26:846-850; Roy, et al. (1993) J. Immunol.
  • CD154 mRNA has been shown to be unstable in activated T lymphocytes, with a half-life ( ⁇ 30 minutes) approximating that seen with interleukins-2 (IL-2; Ford, et al. (1999) J. Immunol. 162:4037-4044; Murakami, et al. (1999) J. Immunol. 163:2667-2673; Rigby, et al. (1999) J. Immunol. 163:4199-4206; Suarez, et al. (1997) Eur. J. Immunol. 27:2822-2829).
  • IL-2 interleukins-2
  • Ford et al. (1999) J. Immunol. 162:4037-4044
  • Murakami, et al. (1999) J. Immunol. 163:2667-2673 Rigby, et al. (1999) J. Immunol. 163:4199-4206
  • Suarez, et al. (1997) Eur
  • cytokine IL-2 and TNF-alpha
  • CD154 mRNA stability and expression are regulated through distinct pathways (Ford, et al. (1999) supra; Lindsten, et al. (1989) Science 244:339-343; Murakami, et al. (1999) supra).
  • a region within the 986 nucleotide human CD154 3′-untranslated region (3′-UTR) confers an increase in the rate of mRNA turnover to chimeric reporter gene constructs in vivo (Hamilton, et al. (2003) Mol. Cell. Biol.; 23 (2):510-25).
  • This region lacks canonical AURE-type sequences, containing a polypyrimidine rich element as well as CA-dinucleotide repeat and polycytidine sequences.
  • PTB human polypyrimidine tract binding protein
  • the murine CD154 (mCD154) 3′-UTR is ⁇ 0.3 kb shorter than its human counterpart, due to a 292 nucleotide insertion present at the 5′ end of the human 3′-UTR.
  • the remaining portion of the human and entire mCD154 3′-UTR exhibits 70% conservation with retention of the polycytidine, polypyrimidine, and CA-dinucleotide repeat regions as well as an AURE that is found immediately 5′ of the polyadenylation signal sequence.
  • Murine CD154 3′-UTR inhibits luciferase mRNA accumulation and protein activity in a comparable manner relative to that seen with the human CD154 3′-UTR. Further, deletion of the polypyrimidine-rich region cis-acting element enhances inhibition of 3′-UTR-dependent gene expression.
  • the present invention embraces methods for modulating the nuclear export or translation of a ribonucleic acid.
  • the methods involve contacting a cell or tissue containing a CA-dinucleotide rich sequence of the CD154 mRNA 3′-untranslated region operatively-linked to a ribonucleic acid with an agent that binds to the CA-dinucleotide rich sequence of the CD154 mRNA 3′-untranslated region or an agent which modulates the level or activity of an hnRNP L protein so that the nuclear export or translation of the ribonucleic acid is modulated.
  • the present invention also encompasses methods for preventing or treating a disease or condition associated with CD154-CD40 interactions. These methods involve administering to a subject in need of treatment an agent which binds to a CA-dinucleotide rich sequence of the CD154 mRNA 3′-untranslated region or an agent which modulates the level or activity of hnRNP L protein so that CD154 translation is inhibited thereby preventing or treating the disease or condition associated with CD154-CD40 interactions.
  • the present invention further provides a method for identifying agents that modulate the level or activity of hnRNP L.
  • This method of the invention involves contacting a test cell containing hnRNP L protein, and a CA-dinucleotide rich sequence of the CD154 mRNA 3′-untranslated region operatively-linked to a nucleic acid encoding a reporter protein, with an agent and detecting reporter protein expression in the test cell.
  • a decrease in reporter protein expression in the test cell contacted with the agent relative to reporter protein expression in a test cell not contacted with the agent indicates that the agent increases the level or activity of hnRNP L in the cell.
  • An increase in reporter protein expression in the test cell contacted with the agent relative to reporter protein expression in a test cell not contacted with the agent indicates that the agent decreases the level or activity of hnRNP L in the cell.
  • the human and murine CD154 3′-UTR are highly conserved, except for the presence of a 293 nucleotide insertion immediately after the translational stop site. Most notable are the presence of adjacent CU- and CA-rich regions.
  • the murine CD154 3′-UTR contains polycytidine and AU-rich element sequences that are expanded relative to its human counterpart.
  • the CA-rich region is of interest as it represents an extended series of CA-dinucleotide repeats, which are almost always intronic. Chimeric reporter gene constructs have indicated that a cis-acting element of the human CD154 3′-UTR maps to a region containing both the CU- and CA-rich domains. This effect was present in multiple cell lines (Jurkat, HeLa) as well as normal human T cells.
  • chimeric luciferase reporter gene constructs were generated and transiently transfected into HeLa cells.
  • the presence of the mCD154 3′-UTR markedly reduced luciferase expression.
  • Prior studies with the human CD154 3′-UTR indicate that cytoplasmic levels of PTB proteins regulate the function of this element.
  • the binding specificity of PTB proteins indicate that the CU-rich domain is the major cis-acting element in the human CD154 3′-UTR.
  • deletion of the CU-rich domain from mCD154 3′-UTR resulted in a decrease rather than an increase in luciferase activity. Deletion of the CA-rich domain provided a similar effect. Accordingly, both the CU- and CA-rich domains in the CD154 3′-UTR function as cis-acting elements.
  • both the CU- and CA-rich domains were deleted.
  • This mutation increased luciferase activity to 171% of that seen with control.
  • Superimposing mutation of the polycytidine (poly C) or ARE sequences in the context of deleting the CU and CA elements in the CD154 3′-UTR had no additional effect on luciferase expression.
  • poly C polycytidine
  • ARE sequences in the context of deleting the CU and CA elements in the CD154 3′-UTR had no additional effect on luciferase expression.
  • Using a HeLa TET-OFFTM system identical constructs were generated containing either the CU- or CA-rich region. HeLa cells were transiently transfected overnight and transcription was inhibited by the addition of doxycycline. Cytoplasmic RNA was collected at time 0 and at various times thereafter.
  • Luciferase mRNA levels measured by real-time RT-PCR indicated that at time 0, steady state levels of cytoplasmic luciferase mRNA were reduced by the presence of CD154 3′-UTR containing either the CU-rich regions.
  • the presence of the mCD154 3′-UTR increased luciferase mRNA turnover relative to controls, as seen with the human 3′-UTR.
  • Deletion of both CU- and CA-rich regions increased luciferase mRNA stability to that of controls. Luciferase mRNA lacking the CA-rich element exhibited increased mRNA turnover relative to controls, possibly due to the retained CU-rich region alone.
  • CA-rich region reduces cytoplasmic mRNA levels in the absence of effects on mRNA stability.
  • Isolated CU-rich and/or CA-rich regions were cloned into the 3′-UTR of the pTRE vector and luciferase activity and mRNA turnover examined.
  • the CU- and CA-rich regions alone were more effective in reducing luciferase activity than the entire CD154 3′-UTR. Expression of the region containing the CU and CA region alone reduced luciferase activity to the same degree.
  • the present invention embraces methods of modulating nuclear export or translation of a ribonucleic acid molecule operatively-linked to a CA-dinucleotide rich sequence of the CD154 mRNA 3′-untranslated region using an agent which binds to the CA-dinucleotide rich sequence or which modulates the level or activity of an hnRNP L protein so that the nuclear export or translation of the ribonucleic acid is modulated.
  • Methods of modulating or regulating translation of an RNA molecule operatively-linked to a CA-dinucleotide repeat of a CD154 3′-UTR encompass both enhancing and inhibiting the translation of said RNA molecule.
  • Binding of an agent, e.g., an siRNA or hnRNP L (GENBANK Accession No. NP — 001005335 or NP — 001524) to the CA-dinucleotide repeat or increasing the expression or activity of hnRNP L via an agent results in inhibition of translation of the RNA molecule.
  • an agent e.g., an siRNA
  • RNA Effects on translation of the RNA can be determined using standard techniques such as western blot analysis of the translated product of the RNA sequence, or if the protein being translated is an enzyme, enzymatic assays can be performed.
  • the ribonucleic acid molecule encodes CD154.
  • binding of an agent to the CA-dinucleotide repeat or increasing the level or activity of hnRNP L by pharmacological agents is contemplated as a useful tool in the treatment of autoimmune and inflammatory diseases which are associated with CD154-CD40 interactions, whereas decreasing the level or activity of hnRNP L by pharmacological agents is contemplated as a useful tool in the treatment of, e.g., cancer, wherein CD40 activation by CD154 is advantageous.
  • the present invention also encompasses methods for preventing or treating a disease or condition associated with B cell CD154-CD40 interactions, i.e., diseases or conditions resulting from enhanced CD40 activation by CD154, or diseases or conditions associated with lack of CD40 activation by CD154.
  • the methods involve administering to a subject in need of treatment an agent which binds to a CA-dinucleotide rich sequence of the CD154 mRNA 3′-untranslated region or an agent that increases the level or activity of hnRNP L protein so that CD154 translation is inhibited thereby preventing or treating the disease or condition associated with CD40 activation by CD154.
  • Diseases or conditions which can be prevented or treated in accordance with the instant method include, but are not limited to, allograft rejection; allergy (including anaphylaxis); atherosclerosis including angina, myocardial infarction, stroke and other conditions of chronic or acute vascular insufficiency; autoimmune conditions including drug-induced lupus, systemic lupus erythematosus, adult rheumatoid arthritis, juvenile rheumatoid arthritis, scleroderma, Sjogren's Syndrome, etc.; and viral diseases that involve B-cells, including Epstein-Barr infection, cancer, and retroviral infection including infection with a human immunodeficiency virus. Because it has been suggested that B cell activation is associated with the induction of human immunodeficiency virus replication from latency, it may be desirable to decrease translation of CD154 mRNA in HIV positive individuals who have not yet developed AIDS or ARC.
  • the subject is a primate, such as a human.
  • the subject is a mammal of commercial importance, or a companion animal or other animal of value.
  • subjects also include, but are not limited to, sheep, horses, cattle, goats, pigs, dogs, cats, rabbits, guinea pigs, hamsters, rats and mice.
  • the agent can be administered as a capsule, intramuscularly, intraperitoneally, subcutaneously, intradermally or applied locally to a wound site. It is also clear that the invention can be used with a skin graft procedure. The skin is a notoriously difficult tissue with which to achieve or maintain engraftment. A preferred route of administration for treating or preventing skin graft rejection is topical, subdermal, intradermal or subcutaneous, though systemic and other routes are also contemplated.
  • Another route of administration for skin graft includes direct application locally (by topical application, immersion or bath, or local injection) into the subject tissue bed, or to the graft tissue itself.
  • High local concentrations of the agent, particularly in areas of lymphatic drainage, are expected to be particularly advantageous.
  • the graft tissue can be transfected or transformed with a recombinant expression vector to overexpress hnRNP L.
  • An effective amount of an agent which binds to a CA-dinucleotide rich sequence of the CD154 mRNA 3 1 -untranslated region or an agent that alters the level or activity of hnRNP L protein is an amount which decreases or inhibits the signs or symptoms of diseases or conditions associated with CD40 activation (e.g., edema, fever, and loss of graft function) and will be dependent on the nature of the agent.
  • Agents useful in accordance with the methods provided herein include, but are not limited to, purified hnRNP L protein, a recombinant expression vector expressing hnRNP L, a recombinant expression vector expressing an siRNA which binds the CA-dinucleotide repeat or hnRNP L RNA, organic molecules, biomolecules including peptides, antibodies, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.
  • An isolated or purified protein hnRNP L protein for administrating PTB or PTB-T proteinadministration to a cell or tissue can be produced by various means.
  • An isolated or purified protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the hnRNP L protein is derived.
  • To be substantially free of cellular material includes preparations of hnRNP L protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. When the hnRNP L protein is recombinantly produced, it is also preferably substantially free of culture medium.
  • Recombinant production of hnRNP L protein typically involves generating a fusion protein such as a GST-hnRNP L in which the hnRNP L protein sequence is fused to the C-terminus of the GST sequence.
  • a fusion protein such as a GST-hnRNP L in which the hnRNP L protein sequence is fused to the C-terminus of the GST sequence.
  • Such fusion proteins can facilitate the purification of recombinant hnRNP L protein.
  • the fusion protein is a hnRNP L protein containing a heterologous signal sequence at its N-terminus.
  • expression and/or secretion of hnRNP L protein can be increased through use of a heterologous signal sequence.
  • a hnRNP L chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques.
  • DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
  • the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers or PCR amplification.
  • PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which are subsequently annealed and reamplified to generate a chimeric gene sequence (see, e.g., Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons, 1992).
  • anchor primers which give rise to complementary overhangs between two consecutive gene fragments which are subsequently annealed and reamplified to generate a chimeric gene sequence
  • many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide).
  • a hnRNP L-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the hnRNP L protein.
  • a recombinant expression vector contains a nucleic acid encoding hnRNP L in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively-linked to the nucleic acid to be expressed.
  • operatively-linked is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell).
  • a regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel (1990) Methods Enzymol. 185:3-7. Regulatory sequences include those which direct constitutive expression of a nucleic acid sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by one of skill in the art that the design of the expression vector depends on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vector can be introduced into a host cell to thereby produce proteins or peptides of hnRNP L, isoforms of hnRNP L, mutant forms of hnRNP L, fusion proteins, and the like.
  • a recombinant expression vector can be designed for expression of hnRNP L protein in prokaryotic or eukaryotic cells.
  • hnRNP L proteins can be expressed in bacterial cells such as E. coli , insect cells (using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel (1990) supra.
  • the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein.
  • Such fusion vectors typically serve to increase expression of recombinant protein; increase the solubility of the recombinant protein; and aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
  • a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
  • enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
  • Typical fusion expression vectors include PGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31-40), PMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
  • PGEX Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31-40
  • PMAL New England Biolabs, Beverly, Mass.
  • pRIT5 Pharmacia, Piscataway, N.J.
  • Suitable inducible non-fusion E. coli expression vectors include pTrc (Amann, et al., (1988) Gene 69:301-315) and pET ld (Studier, et al. (1990) Methods Enzymol. 185:60-89).
  • Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter.
  • Target gene expression from the pET lid vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21 (DE3) or HMS174 (DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.
  • yeast expression vector is also contemplated.
  • yeast Saccharomyces cerevisiae examples include pYepSec 1 (Baldari, et al. (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz (1982) Cell 30:933-943), pJRY88 (Schultz, et al. (1987) Gene 54:113-123), pYES2 (INVITROGENTM Corp., San Diego, Calif.), and picZ (INVITROGENTM Corp., San Diego, Calif.).
  • hnRNP L protein can be expressed in insect cells using baculovirus expression vectors.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith, et al. (1983) Mol. Cell. Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
  • nucleic acid molecules encoding hnRNP L are expressed in mammalian cells using a mammalian expression vector.
  • hnRNP L expression in mammalian cells provides a means of purifying the proteins as well as a means of modulating the endogenous levels of hnRNP L protein in a cell.
  • mammalian expression vectors include any one of the well-known recombinant viral vectors, pCDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman, et al. (1987) EMBO J. 6:187-195).
  • the expression vector's control functions are often provided by viral regulatory elements.
  • promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
  • suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, et al. Molecular Cloning: A Laboratory Manual. 2 nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
  • the recombinant mammalian expression vector may further be capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
  • tissue-specific regulatory elements are known in the art.
  • suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J.
  • promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the ⁇ -fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
  • hnRNP L expression can be decreased to modulate the levels of hnRNP L present in the cell.
  • a recombinant expression vector harboring a nucleic acid encoding hnRNP L, or an iRNA target sequence thereof, cloned into the expression vector in an antisense orientation is also provided. That is, the nucleic acid encoding hnRNP L, or a target fragment thereof, is operatively-linked to a regulatory sequence in a manner which allows for expression (by transcription of the nucleic acid sequence) of an RNA molecule which is antisense to hnRNP L mRNA.
  • Regulatory sequences operatively-linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue-specific or cell type-specific expression of antisense RNA.
  • the antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
  • Host cells into which a hnRNP L nucleic acid can be introduced e.g., a hnRNP L nucleic acid within a vector (e.g., a recombinant expression vector) or a hnRNP L nucleic acid containing sequences which allow it to homologously recombined into a specific site of the host cell's genome, are further contemplated.
  • the terms host cell and recombinant host cell are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and transfection are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. supra and other laboratory manuals.
  • a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the nucleic acid of interest.
  • selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Nucleic acids encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a hnRNP L protein or can be introduced on a separate vector.
  • Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
  • a host cell such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an hnRNP L protein.
  • the host cells can also be used to produce non-human transgenic animals.
  • a host cell is a fertilized oocyte or an embryonic stem cell into which hnRNP L-coding sequences have been introduced.
  • Such host cells can then be used to create non-human transgenic animals in which exogenous hnRNP L sequences have been introduced into their genome or homologous recombinant animals in which endogenous hnRNP L sequences have been altered.
  • Such animals are useful for studying the function and/or activity of a hnRNP L protein and for identifying and/or evaluating modulators of hnRNP L activity.
  • a transgenic animal is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene.
  • Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like.
  • a transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.
  • a homologous recombinant animal is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous hnRNP L gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
  • a transgenic animal can be created by introducing a hnRNP L-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal.
  • a non-human homologue of a human hnRNP L gene such as a rat or mouse hnRNP L gene, can be used as a transgene.
  • Intronic sequences and polyadenylation signals may also be included in the transgene to increase the efficiency of expression of the transgene.
  • a tissue-specific regulatory sequence(s) can be operatively-linked to a hnRNP L transgene to direct expression of a hnRNP L protein to particular cells.
  • Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; 4,873,191; and in Hogan, Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals.
  • a transgenic founder animal can be identified based upon the presence of a hnRNP L transgene in its genome and/or expression of hnRNP L mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a hnRNP L protein can further be bred to other transgenic animals carrying other transgenes.
  • a vector which contains at least a portion of a hnRNP L gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the hnRNP L gene.
  • the hnRNP L gene can be a human gene or a non-human homologue of a human hnRNP L gene.
  • a mouse hnRNP L gene can be used to construct a homologous recombination nucleic acid molecule, e.g., a vector, suitable for altering an endogenous hnRNP L gene in the mouse genome.
  • the homologous recombination nucleic acid molecule may be designed such that, upon homologous recombination, the endogenous hnRNP L gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a knock out vector).
  • the homologous recombination nucleic acid molecule can be designed such that, upon homologous recombination, the endogenous hnRNP L gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous hnRNP L protein).
  • the altered portion of the hnRNP L gene is flanked at its 5′ and 3′ ends by additional nucleic acid sequence of the hnRNP L gene to allow for homologous recombination to occur between the exogenous hnRNP L gene carried by the homologous recombination nucleic acid molecule and an endogenous hnRNP L gene in a cell, e.g., an embryonic stem cell or fetal fibroblast.
  • the additional flanking hnRNP L nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene.
  • homologous recombination nucleic acid molecule typically, several kilobases of flanking DNA (both at the 5′ and 3′ ends) are included in the homologous recombination nucleic acid molecule (see, e.g., Thomas and Capecchi (1987) Cell 51:503).
  • the homologous recombination nucleic acid molecule is introduced into a cell, e.g., an embryonic stem cell line, by for example electroporation, and cells in which the introduced hnRNP L gene has homologously recombined with the endogenous hnRNP L gene are selected (see, e.g., Li, et al. (1992) Cell 69:915).
  • the selected cells can then be injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley, In: Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, E. J. ed. (IRL, Oxford, 1987) pp. 113-152).
  • a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
  • Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene.
  • homologous recombination nucleic acid molecules e.g., vectors, or homologous recombinant animals are well-known (see, e.g., Bradley (1991) Current Opin. Biotechnol. 2:823-829; WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.
  • a method for identifying an agent that modulates the level or activity of hnRNP L is also encompassed by the instant invention.
  • the method involves contacting a test cell containing hnRNP L protein, and a CA-dinucleotide rich sequence of the CD154 mRNA 3′-untranslated region operatively-linked to a nucleic acid encoding a reporter protein, with an agent and detecting reporter protein expression in the test cell.
  • a decrease in reporter protein expression in the test cell contacted with the agent relative to reporter protein expression in a test cell not contacted with the agent indicates that the agent increases the level or activity of hnRNP L in the cell.
  • test cells expressing a reporter which can be used in accordance with the method of the invention are, in certain embodiments, mammalian cells including human cells.
  • the reporter gene sequence(s) can be inserted into a recombinant expression vector according to methods disclosed herein. More than one reporter gene can be inserted into the construct such that the test cells containing the resulting construct can be assayed by different means.
  • the test cells which contain the nucleic acid encoding the reporter and which express the reporter can be identified by at least four general approaches; detecting DNA-DNA or DNA-RNA hybridization; observing the presence or absence of marker gene functions (e.g., resistance to antibiotics); assessing the level of transcription as measured by the expression of reporter mRNA transcripts in the host cell; and detecting the reporter gene product as measured by immunoassay or by its biological activity.
  • test cells can be cultured under standard conditions of temperature, incubation time, optical density, plating density and media composition corresponding to the nutritional and physiological requirements of the cells.
  • conditions for maintenance and growth of the test cell can be different from those for assaying candidate test compounds in the screening methods of the invention.
  • Modified culture conditions and media are used to facilitate detection of the expression of a reporter molecule. Any techniques known in the art can be applied to establish the optimal conditions.
  • a reporter gene refers to any genetic sequence that is detectable and distinguishable from other genetic sequences present in test cells.
  • the reporter nucleic acid encodes a protein that is readily detectable either by its presence, or by its activity that results in the generation of a detectable signal.
  • a nucleic acid encoding the reporter is used in the invention to monitor and report the translation of an RNA operatively-linked to a CA-dinucleotide rich sequence of a CD154 3′-untranslated region in test cells.
  • a variety of enzymes can be used as reporters including, but are not limited to, ⁇ -galactosidase (Nolan, et al. (1988) Proc. Natl. Acad. Sci. USA 85:2603-2607), chloramphenicol acetyltransferase (CAT; Gorman, et al. (1982) Molecular Cell Biology 2:1044; Prost, et al. (1986) Gene 45:107-111), ⁇ -lactamase, ⁇ -glucuronidase and alkaline phosphatase (Berger, et al. (1988) Gene 66:1-10; Cullen, et al. (1992) Methods Enzymol. 216:362-368).
  • ⁇ -galactosidase Nolan, et al. (1988) Proc. Natl. Acad. Sci. USA 85:2603-2607
  • CAT chloramphenicol acetyltransferase
  • CAT chloram
  • the amount of enzyme present can be measured via its enzymatic action on a substrate resulting in the formation of a detectable reaction product.
  • the methods of the invention provide means for determining the amount of reaction product, wherein the amount of reaction product generated or the remaining amount of substrate is related to the amount of enzyme activity.
  • enzymes such as ⁇ -galactosidase, ⁇ -glucuronidase and ⁇ -lactamase
  • fluorogenic substrates are available that allow the enzyme to covert such substrates into detectable fluorescent products.
  • bioluminescent, chemiluminescent and fluorescent proteins can also be used as light-emitting reporters in the invention.
  • exemplary light-emitting reporters which are enzymes and require cofactor(s) to emit light, include, but are not limited to, the bacterial luciferase (luxAB gene product) of Vibrio harveyi (Karp (1989) Biochim. Biophys. Acta 1007:84-90; Stewart, et al. (1992) J. Gen. Microbiol. 138:1289-1300), and the luciferase from firefly, Photinus pyralis (De Wet, et al. (1987) Mol. Cell. Biol. 7:725-737).
  • GFP green fluorescent protein
  • Victoria aequoria Cholfie, et al. (1994) Science 263:802-805
  • modified GFPs Heim, et al. (1995) Nature 373:663-4; WO 96/23810
  • luxABCDE Photorhabdus luminescens lux operon
  • an exemplary reporter construct contains the CA-dinucleotide rich sequence of a CD154 3′-untranslated region which regulates the translation of and therefore the expression of the reporter luciferase.
  • a screening assay of the invention can be carried out by culturing a test cell containing a nucleic acid encoding luciferase operatively-linked to a CA-dinucleotide rich sequence of a CD154 3′-untranslated region; adding a test agent to a point of application, such as a well, in the plate and incubating the plate for a time sufficient to allow the test agent to effect luciferase mRNA translation; detecting luminescence of the test cells contacted with the test agent, wherein luminescence indicates expression of the luciferase polypeptide in the test cells; and comparing the luminescence of test cells not contacted with the test agent.
  • a decrease in luminescence of the test cell contacting the test agent relative to the luminescence of test cells not contacting the test agent indicates that the test agent causes a decrease in the level or activity of hnRNP L.
  • An increase in luminescence of the test cell contacting the test agent relative to the luminescence of test cells not contacting the test agent indicates that the test agent causes an increase in the level or activity of hnRNP L.
  • Agents which can be screened using the method provided herein encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Agents encompass functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The agents often contain cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Agents can also be found among biomolecules including peptides, antibodies, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Agents are obtained from a wide variety of sources including libraries of natural or synthetic compounds.
  • reagents such as salts and neutral proteins can be included in the screening assays.
  • reagents that otherwise improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, anti-microbial agents, and the like can be used.
  • the mixture of components can be added in any order that provides for the requisite binding.
  • antibodies against the hnRNP L can serve as the agent to inhibit (antagonize) or stimulate (agonize) hnRNP L activity.
  • Whole hnRNP L or an epitope bearing fragment thereof can be used as an immunogen to produce antibodies immunospecific for hnRNP L.
  • Various techniques well-known in the art can be used routinely to produce antibodies (Kohler and Milstein (1975) Nature 256:495-497; Kozbor, et al. (1983) Immunol. Today 4:72; Cole, et al. (1985) In: Monoclonal Antibodies and Cancer Therapy, pp 77-96).

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
US12/064,471 2005-09-13 2006-09-11 Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat Abandoned US20090221673A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/064,471 US20090221673A1 (en) 2005-09-13 2006-09-11 Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71670805P 2005-09-13 2005-09-13
US12/064,471 US20090221673A1 (en) 2005-09-13 2006-09-11 Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat
PCT/US2006/035260 WO2007033058A2 (fr) 2005-09-13 2006-09-11 Compositions et procédés de régulation de la traduction de l'arn à l'aide de répétitions de dinucléotides ca de cd154

Publications (1)

Publication Number Publication Date
US20090221673A1 true US20090221673A1 (en) 2009-09-03

Family

ID=37865475

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/064,471 Abandoned US20090221673A1 (en) 2005-09-13 2006-09-11 Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat
US11/854,148 Active 2030-04-18 US9109228B2 (en) 2005-09-13 2007-09-12 Compositions and methods for regulating RNA translation via CD154 CA-dinucleotide repeat

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/854,148 Active 2030-04-18 US9109228B2 (en) 2005-09-13 2007-09-12 Compositions and methods for regulating RNA translation via CD154 CA-dinucleotide repeat

Country Status (2)

Country Link
US (2) US20090221673A1 (fr)
WO (1) WO2007033058A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067785A1 (fr) * 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Peptide synthétique de fixation de CD154 chez l'homme et utilisations associées

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096282A1 (en) * 1997-04-21 2005-05-05 Lewin Alfred S. Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases
US7022487B2 (en) * 2002-01-17 2006-04-04 Trustees Of Dartmouth College Compositions and methods for regulating RNA stability using polypyrimidine tract proteins
US7345027B2 (en) * 2002-07-24 2008-03-18 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiogenesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359461A1 (fr) * 1999-01-15 2000-07-20 Medstar Research Institute Inhibition du developpement de vaisseaux microscopiques dans des parois vasculaires
DK1407044T4 (en) * 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096282A1 (en) * 1997-04-21 2005-05-05 Lewin Alfred S. Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases
US7022487B2 (en) * 2002-01-17 2006-04-04 Trustees Of Dartmouth College Compositions and methods for regulating RNA stability using polypyrimidine tract proteins
US7345027B2 (en) * 2002-07-24 2008-03-18 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiogenesis

Also Published As

Publication number Publication date
US20090130088A1 (en) 2009-05-21
WO2007033058A3 (fr) 2007-10-25
WO2007033058A2 (fr) 2007-03-22
US9109228B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
AU2022221378B2 (en) Humanized SIRPA-IL15 knockin mice and methods of use thereof
JP2009537139A (ja) 置換されたテトラサイクリン化合物を用いて、遺伝子または遺伝子産物の発現を制御する方法
AU1409099A (en) Rapidly degrading gfp-fusion proteins and methods of use
WO2007121364A2 (fr) Polypeptides tetramerisants et procedes d'utilisation
US8278107B2 (en) Compositions and methods for regulating RNA translation via CD154 CA-dinucleotide repeat
Haller et al. Structure, chromosomal localization and expression of the mouse regulator of G-protein signaling10 gene (mRGS10)
US20090221673A1 (en) Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat
US7022487B2 (en) Compositions and methods for regulating RNA stability using polypyrimidine tract proteins
Long et al. Stimulation of the murine Uchl1 gene promoter by the B-Myb transcription factor
EP1867716B1 (fr) Animal modelé dans lequel l'évolution d'un état pathologique peut être observé en temps réel, gène chimère utilisé pour ce faire et utilisation correspondante
US20180348231A1 (en) Ligand inducible polypeptide coupler system
WO2009036130A1 (fr) Compositions et procédés de régulation de la traduction de l'arn à l'aide de répétitions de dinucléotide ca de cd154
JPH114638A (ja) トランスジェニック非ヒト動物からの高次転写複合体の精製
US20030041337A1 (en) Transgenic animals containing a dominant negative mutant form of the p85 subunit of PI-3 kinase
RU2822370C2 (ru) Гуманизированные мыши с нокином sirpa-il15 и способы их использования
WO2005026718A1 (fr) Banques de cellules souches
JP4602772B2 (ja) Ｗｔ１遺伝子トランスジェニック動物

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRUSTEES OF DARTMOUTH COLLEGE, NEW HAMPSHIRE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RIGBY, WILLIAM F.C.;REEL/FRAME:020551/0964

Effective date: 20080213

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:DARTMOUTH COLLEGE;REEL/FRAME:025667/0223

Effective date: 20070327

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:TRUSTEES OF DARTMOUTH COLLEGE;REEL/FRAME:059281/0831

Effective date: 20211104